Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Elicio Therapeutics, Inc. - Common Stock (NQ:ELTX)

9.290 +0.040 (+0.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 80,851
Open 9.290
Bid (Size) 9.000 (1)
Ask (Size) 9.900 (2)
Prev. Close 9.250
Today's Range 9.165 - 9.410
52wk Range 4.050 - 12.62
Shares Outstanding 29,798,399
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
From Elicio Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
+80.7%
+80.7%
1 Month
-15.1%
-15.1%
3 Month
-5.3%
-5.3%
6 Month
+85.1%
+85.1%
1 Year
+123.3%
+123.3%

More News

Read More
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio (ELTX) Q2 Loss Beats Estimates
Via The Motley Fool
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis
From Elicio Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Secures $10 Million in Financing
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires
From Elicio Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer
From Elicio Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Elicio Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
From Elicio Therapeutics Inc.
Via GlobeNewswire
Why INNOVATE Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Elicio Therapeutics, Inc. - Common Stock publicly traded?
Yes, Elicio Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Elicio Therapeutics, Inc. - Common Stock trade on?
Elicio Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Elicio Therapeutics, Inc. - Common Stock?
The ticker symbol for Elicio Therapeutics, Inc. - Common Stock is ELTX on the Nasdaq Stock Market
What is the current price of Elicio Therapeutics, Inc. - Common Stock?
The current price of Elicio Therapeutics, Inc. - Common Stock is 9.290
When was Elicio Therapeutics, Inc. - Common Stock last traded?
The last trade of Elicio Therapeutics, Inc. - Common Stock was at 10/31/25 04:00 PM ET
What is the market capitalization of Elicio Therapeutics, Inc. - Common Stock?
The market capitalization of Elicio Therapeutics, Inc. - Common Stock is 276.83M
How many shares of Elicio Therapeutics, Inc. - Common Stock are outstanding?
Elicio Therapeutics, Inc. - Common Stock has 277M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.